BRIEF published on 01/02/2025 at 09:19, 11 months 3 days ago CHEPLAPHARM Appoints Tamás Szóga as VP Commercial Management Expansion CHEPLAPHARM Tamás Szóga VP Commercial Pharmaceutical Strategy
PRESS RELEASE published on 01/02/2025 at 09:14, 11 months 3 days ago CHEPLAPHARM expands Management with Tamás Szóga as VP Commercial CHEPLAPHARM expands management team by appointing Tamás Szóga as VP Commercial, responsible for strategic planning and development of Global Sales division Global Sales Strategic Planning CHEPLAPHARM Tamás Szóga VP Commercial
BRIEF published on 12/16/2024 at 08:53, 11 months 20 days ago CHEPLAPHARM Acquires Gemzar from Lilly Acquisition Oncology Eli Lilly CHEPLAPHARM Gemzar
BRIEF published on 12/16/2024 at 08:53, 11 months 20 days ago CHEPLAPHARM acquiert Gemzar auprès de Lilly Acquisition Oncologie Eli Lilly CHEPLAPHARM Gemzar
PRESS RELEASE published on 12/16/2024 at 08:48, 11 months 20 days ago CHEPLAPHARM acquires Gemzar from Lilly CHEPLAPHARM acquires Gemzar from Lilly, expanding its oncology portfolio with a proven chemotherapeutic agent for various types of cancer Acquisition Oncology CHEPLAPHARM Chemotherapy Gemzar
BRIEF published on 11/08/2024 at 10:50, 1 year ago Sebastian Braun Honored as EY Entrepreneur of the Year Entrepreneurship Family Business CHEPLAPHARM EY Award Sebastian Braun
BRIEF published on 11/08/2024 at 10:50, 1 year ago Sebastian Braun élu Entrepreneur de l'année par EY CHEPLAPHARM Entreprise Familiale Entreprenariat Prix EY Sébastien Braun
PRESS RELEASE published on 11/08/2024 at 10:45, 1 year ago SEBASTIAN BRAUN WINS EY ENTREPRENEUR OF THE YEAR Sebastian Braun, Chairman of CHEPLAPHARM Group, wins EY Entrepreneur of the Year in 'family business' category. Recognized for outstanding leadership and business growth Entrepreneurship Business Award EY Entrepreneur Of The Year Sebastian Braun CHEPLAPHARM Group
BRIEF published on 07/17/2024 at 12:19, 1 year 4 months ago CHEPLAPHARM réorganise son équipe de direction Chaîne D'approvisionnement Développement De L'entreprise Pharmaceutique Gestion CHEPLAPHARM
BRIEF published on 07/17/2024 at 12:19, 1 year 4 months ago CHEPLAPHARM Reorganizes Management Team Pharmaceutical Supply Chain Management Corporate Development CHEPLAPHARM
Published on 12/05/2025 at 19:20, 17 minutes ago The Multi-Sector Validation Shock: Why SMX Became Impossible for Markets to Ignore
Published on 12/05/2025 at 18:45, 52 minutes ago Four Global Markets, One Engine: SMX Just Redefined What a Supply Chain Can Prove
Published on 12/05/2025 at 18:20, 1 hour 17 minutes ago NuRAN Announces Intention to Complete Consolidation in Preparation to the Restructuring Transaction
Published on 12/05/2025 at 18:00, 1 hour 37 minutes ago SMX: A New Supply Chain Reality in the World's Four Largest Markets
Published on 12/05/2025 at 17:15, 2 hours 22 minutes ago TRX GOLD Attending the 3rd Annual DealFlow Discovery Conference
Published on 12/05/2025 at 18:58, 39 minutes ago EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:15, 1 hour 21 minutes ago Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 17:46, 1 hour 50 minutes ago Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds
Published on 12/05/2025 at 17:18, 2 hours 19 minutes ago La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 2 hours 19 minutes ago The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 4 hours 26 minutes ago Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 4 hours 26 minutes ago Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 5 hours 38 minutes ago RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE
